Erythema News and Research

RSS

Efficacy and safety of a 3rd dose of mRNA-1273 SARS-CoV-2 vaccine

In a recent study posted to the Research Square* preprint server, researchers tested the safety and immunogenicity of a third dose of coronavirus disease 2019 (COVID-19) prototype messenger ribonucleic acid (mRNA)-1273 versus a variant vaccine and a bivalent vaccine formulation.

5 May 2022

Assessing the association of COVID-19 and Immunoglobulin A vasculitis in children

In a recent study posted to the Research Square* preprint server, researchers conducted a systematic review to investigate any association between immunoglobulin A (IgA) vasculitis and coronavirus disease 2019 (COVID-19) in children.

8 Feb 2022

Symptoms after a third mRNA vaccine among patients with inflammatory bowel disease

Researchers published a report wherein they assessed the symptomology post a booster dose of mRNA vaccines in adults with IBD.

10 Dec 2021

Safety and immunogenicity of COVID-19 peptide vaccine

In a study published in Nature, researchers from University Hospital Tübingen have been investigating the results from a Phase I trial for a new vaccine against SARS-CoV-2 variants.

25 Nov 2021

Three doses of COVID-19 mRNA vaccination safe in high-risk populations

A new study determines the safety of an additional vaccine among individuals who previously received two doses of mRNA-based COVID-19 vaccines.

15 Nov 2021

Influenza and COVID vaccines can be co-administered in older adults without causing severe side effects

Researchers evaluate the safety and immunogenicity of an influenza vaccine and mRNA-based COVID-19 vaccine that were administered concomitantly.

3 Nov 2021

Large study of COVID vaccine side effects in Sweden

Recently, researchers from Sweden reported population-based, age- and sex-specific background incidence rates of conditions that represent potential COVID-19 vaccine adverse events of special interest (AESI) in the general Swedish population with the help of registered data. This study is published on the medRxiv* preprint server.

6 Oct 2021

FDA approves an intravenous medication to treat patients with Pompe disease

Today, the U.S. Food and Drug Administration approved Nexviazyme (avalglucosidase alfa-ngpt) for intravenous infusion to treat patients 1 year of age and older with late-onset Pompe disease.

6 Aug 2021

Intradermal administration of low-dose mRNA COVID-19 vaccine induces strong immune response, study finds

Scientists in the Netherlands recently conducted an open-level, randomized-controlled trial to evaluate the safety and immunogenicity of fractional intradermal doses of the mRNA-based COVID-19 vaccine mRNA-1273 (Moderna). The trial findings reveal that the fractional dose regimen of the Moderna vaccine is well tolerated and safe and is capable of inducing robust antibody responses in vaccine recipients. The study is currently available on the medRxiv* preprint server.

2 Aug 2021

mRNA COVID-19 vaccines may increase patients' concerns about side effects

Vivid photos of the red "COVID arm" rash and reports of facial swelling in patients who have received dermatological fillers after Pfizer-BioNTech or Moderna vaccination for COVID-19 may increase patients' concerns about mRNA vaccine side effects and contribute to vaccine hesitancy.

23 Jun 2021

Benefits of COVID-19 vaccination outweigh the complications, long-term effects of the disease

An international study, headed by Antonio Hernández, Professor of the Department of Legal Medicine, Toxicology and Physical Anthropology of the University of Granada, has reviewed the assessment reports of the European Medicines Agency regarding the Coronavirus vaccines produced by Pfizer, Moderna, and AstraZeneca.

21 Jun 2021

FDA approves Stratagraft for thermal burn treatment in adult patients

Today, the U.S. Food and Drug Administration approved StrataGraft for the treatment of adult patients with thermal burns containing intact dermal elements (remaining deep skin layers) for which surgical intervention is clinically indicated (also referred to as deep partial thickness burns).

15 Jun 2021

COVID-19 symptoms in the feet

In a review paper recently uploaded to the Journal of Clinical Medicine by Jimenez-Cebrian et al. (May 19th, 2021), the clinical manifestations of COVID-19 in feet, in particular, are reviewed, finding that vascular, dermatological, and neurological symptoms have been widely reported.

6 Jun 2021

Despite all the talk, Covid vaccination does not infect people with shingles

Posts are showing up all over social media tying Covid-19 vaccinations to shingles and other painful skin disorders.

30 Apr 2021

Study observes increase in Lyme disease-causing ticks across California’s woodlands and beaches

US-based researchers – at Colorado State University and the Northern Arizona University – have discovered that disease-causing ticks are finding their way onto beachfront properties, including infestations in woodlands and beaches around North California.

28 Apr 2021

Clofazimine inhibits coronaviruses including SARS-CoV-2, study finds

Researchers at the University of Hong Kong found that Clofazimine, a lipophilic antimicrobial riminophenazine dye used in combination with agents like rifampicin and dapsone to treat leprosy, inhibits coronaviruses, including the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19 disease.

21 Mar 2021

Grape consumption offers protection against UV skin damage

A recent human study published in the Journal of the American Academy of Dermatology found that consuming grapes protected against ultraviolet (UV) skin damage.

5 Feb 2021

Previous SARS-CoV-2 infection may negate need for two vaccine doses

Researchers in the United States have shown that two doses of vaccine may not be necessary to protect against coronavirus disease 2019 (COVID-19) among people who have already been infected with the causative agent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

2 Feb 2021

FDA approves first adjuvant treatment for patients with non-small cell lung cancer

Today, the U.S. Food and Drug Administration approved Tagrisso (osimertinib) as the first adjuvant treatment for patients with non-small cell lung cancer whose tumors have a specific type of genetic mutation.

18 Dec 2020

Chilblain-like skin lesions reported in adolescents and young adults during the pandemic

A team of investigators in the Department of Dermatology, Hospital Infantil Universitario Niño Jesús, Madrid, Spain and Dermatologia Pediatrica Association, Bari, Italy, say acral ischemic lesions, similar to chilblains, have been reported across the globe throughout the COVID-19 pandemic.

17 Nov 2020